Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing

Funding to support Phase 2 clinical trials of the company's PSGL-1 inhibitor, SelK2, in multiple indications OKLAHOMA CITY, April 18, 2018 -- (Healthcare Sales & Marketing Network) -- Tetherex Pharmaceuticals, Inc., a privately held biopharmaceutical c... Biopharmaceuticals, Venture Capital Tetherex Pharmaceuticals, venous thromboembolism, PSGL-1, SelK2
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news